Something’s in your coffee that’s linked to cancer
There’s something in your coffee aside from caffeine that may be very important for your health. Introducing trigonelline or “trig” for short identified by scientists at Texas AgriLife Research.
So what is so special about trig? Well, for one thing, it acts like the female hormone estrogen. And because it is estrogenic, it can be a contributing factor to estrogen-dependent breast cancer but can help prevent colon cancer.
Does that mean we should stop (or step up) drinking coffee? Not so fast according to Dr. Clinton Allred, nutrition scientist at AgriLife Research.
Trig is natural compound used in traditional Indian medicine to relieve symptoms in postmenopausal women. However, the estrogen-mimicking properties of trig is surprising since its chemical structure is not similar at all to estradiol, one of the three estrogen hormones.
Trig is found in coffee beans but the amount of this estrogenic compound in your cup of coffee will depend on the following:
- The variety of coffee beans. Trig is found in the two main types of bans consumed in the US.
- The method of roasting the coffee beans. The more the bean is roasted, the less trig is contained.
- The method of brewing. Trig has been detected in a normal cup of brewed coffee.
How do estrogenic compounds such as trig affect cancer? Well, “Estrogen-dependent tumors in the presence of estradiol will grow faster,” according to Dr. Allred. His research team observed this in a series of lab experiments. Trig is definitely estrogenic even at low concentrations.
The researchers caution against jumping into conclusions and misconceptions:
The researchers believe these behaviors are not advisable. The latter is especially dangerous since women might have estrogen- dependent breast cancer without even knowing it. It takes 30 years from the start of a tumor until diagnosis.
But not everything about trig is bad. Estrogenic compounds have been shown to prevent colon cancer formation. Thus, trig is a potential treatment for colon cancer provided the patient does not have estrogen-dependent cancer.
